2. Signaling Pathways
  3. Epigenetics
    JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
    Stem Cell/Wnt
  4. JAK
  5. JAK3 Isoform

JAK3

 

JAK3 Related Products (86):

Cat. No. Product Name Effect Purity
  • HY-50856
    Ruxolitinib
    		Inhibitor 99.99%
    Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3.
  • HY-40354
    Tofacitinib
    		Inhibitor 99.99%
    Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.
  • HY-15315
    Baricitinib
    		Inhibitor 99.97%
    Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.
  • HY-19569
    Upadacitinib
    		Inhibitor 99.96%
    Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM).
  • HY-50858
    Ruxolitinib phosphate
    		Inhibitor 99.98%
    Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.
  • HY-152080
    TUL01101
    		Inhibitor
    TUL01101 is a potent, selective and orally active JAK1 inhibitor, with an IC50s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
  • HY-108342
    PF-00956980
    		Inhibitor
    PF-00956980 is a reversible pan-JAK inhibitor with IC50 values of 2.2, 23.1 and 59.9 μM for JAK1, JAK2 and JAK3, respectively.
  • HY-18949
    JI6
    		Inhibitor
    JI6 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.
  • HY-40354A
    Tofacitinib citrate
    		Inhibitor 99.98%
    Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively.
  • HY-10961
    Momelotinib
    		Inhibitor 98.93%
    Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50a of 11 nM and 18 nM,respectively.
  • HY-16379
    Pacritinib
    		Inhibitor 99.93%
    Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM).
  • HY-18300
    Filgotinib
    		Inhibitor 99.37%
    Filgotinib (GLPG0634) is a selective and orally active JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
  • HY-100754
    Ritlecitinib
    		Inhibitor 99.98%
    Ritlecitinib (PF-06651600) is an orally active and selective JAK3 inhibitor with an IC50 of 33.1 nM.
  • HY-19568
    Peficitinib
    		Inhibitor 99.43%
    Peficitinib (ASP015K) is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.
  • HY-50514
    AT9283
    		Inhibitor 99.70%
    AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM).
  • HY-13034
    Gandotinib
    		Inhibitor 99.82%
    Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM.
  • HY-14435
    Pyridone 6
    		Inhibitor 98.84%
    Pyridone 6 is a pan-JAK inhibitor, which potently inhibits the JAK kinase family, with IC50s of 1 nM for JAK2 and TYK2, 5 nM for JAK3, and 15 nM for JAK1, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.
  • HY-15999
    Cerdulatinib
    		Inhibitor 98.96%
    Cerdulatinib (PRT062070) is a selective Tyk2 inhibitor with an IC50 of 0.5 nM.
  • HY-109053
    Delgocitinib
    		Inhibitor 99.76%
    Delgocitinib (JTE-052) is a specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.
  • HY-10410
    TG101209
    		Inhibitor 99.22%
    TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.